Physician profile
Michael J Lyons
NPI 1306834650
$1,347.72
in general payments reported to CMS, 2019-2025
24 companies · $299 in 2025
The $299 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.06 · 2020: $20.95 · 2021: $137 · 2022: $272 · 2023: $277 · 2024: $299 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $874.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $874.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $215.14 | 2023-2024 | Azstarys |
| Glaxosmithkline, LLC. | $160.07 | 2020-2025 | Bexsero, Fluarix Quadrivalent, Pediarix |
| Pfizer INC. | $85.50 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $83.16 | 2022 | |
| Merck Sharp & Dohme LLC | $79.46 | 2019-2025 | Gardasil 9, M-M-R II, Vaxelis |
| Collegium Pharmaceutical, INC. | $79.40 | 2025 | Jornay Pm |
| Kaleo, INC. | $66.69 | 2022-2023 | Auvi-Q |
| Ironshore Pharmaceuticals INC. | $62.66 | 2019-2021 | |
| Hologic Sales and Service, LLC | $60.31 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Seqirus USA INC | $58.88 | 2021-2023 | Flucelvax Quadrivalent |
| Sanofi-Aventis U.S. LLC | $49.14 | 2023-2025 | |
| Sanofi Pasteur INC. | $46.72 | 2024-2025 | |
| Ars Pharmaceuticals Operations, INC. | $44.55 | 2025 | Neffy |
| Exeltis, USA INC. | $43.26 | 2024 | Slynd |
| Vertical Pharmaceuticals, LLC | $38.11 | 2024-2025 | Relexxii |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $24.69 | 2024 | Voxzogo 1.2mg |
| Mayne Pharma Commercial LLC | $23.97 | 2022 | |
| Rhythm Pharmaceuticals, INC. | $23.78 | 2022 | |
| Novo Nordisk INC | $20.14 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $19.86 | 2023 | Flumist Quadrivalent |
| Verrica Pharmaceuticals INC. | $19.29 | 2024 | Ycanth |
| Dermira, INC. | $15.12 | 2019 | |
| Avion Pharmaceuticals | $15.10 | 2023 | Methylphenidate Hydrochloride |
| Tris Pharma INC | $12.72 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.